news, journals and articles from all over the world.
A recent study has uncovered the molecular mechanisms behind osteocyte death in melanoma bone metastasis, revealing that ferroptosis—an iron-dependent form of cell death—plays a central role in the destruction of bone cells. The research identifies the HIF1α-HMOX1 axis as a critical pathway that induces excessive autophagy and iron overload, leading to osteocyte demise.
NEW YORK, December 4, 2024 – Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments:
Yale researchers made an unexpected discovery—turncoat T cells that help a tumor evade other cancer-fighting immune T cells—in a study of patients living with advanced melanoma that was published Nov. 28 in Nature Immunology.
Key mechanism of resistance to BRAF-targeted melanoma therapy discovered. Potential for developing new cancer therapies with high efficacy by regulating polyamine biosynthesis to suppress resistance.
UCLA’s Dr. Roger Lo was awarded a $2 million grant from the National Institutes of Health to investigate innovative strategies to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors, a common treatment for patients with melanomas that carry the BRAFV600 mutation.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
Age-related changes in the fibroblasts, cells that create the skin’s structure, contribute to the development of aggressive, treatment-resistant melanoma in males, according to research in mice by the Johns Hopkins Kimmel Cancer Center.
About 8 to 10 million Americans over age 40 have an overabundance of cloned white blood cells, or lymphocytes, that hamper their immune systems. Although many who have this condition — called monoclonal B-cell lymphocytosis (MBL) — do not experience any symptoms, a new study shows they may have an elevated risk for several health complications, including melanoma, a form of skin cancer.
A new tool for monitoring immune health patterns over time reveals how a pair of checkpoint inhibitor therapies works together to recruit new cancer-fighting T cells with every infusion.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
After a cold and rainy winter, it’s refreshing to plan summertime outdoor activities or a day at the beach soaking up the sun. But it’s important to remember that too much sun exposure can be harmful.
Jeffrey M. Farma, MD, FACS, of the American College of Surgeons’ Commission on Cancer offers three tips to protect yourself while enjoying time outdoors.
The Wistar Institute’s Dr. Noam Auslander was awarded a $600,000 Women Scientists Innovation Award for Cancer Research grant from the V Foundation for Cancer Research to support the next three years of her research, which will use proteins of gut bacteria to predict immunotherapy benefit in melanoma.
Brian Ingham was only 32 years old when a board-certified dermatologist discovered melanoma on his back during a routine visit to get a tattoo removed in late 2023. The Washington, D.C.-area military pilot said he knew he was at an increased risk as his mother was recently diagnosed with advanced melanoma that same year.
Breakthrough one-time cancer treatment option for select patients with metastatic melanoma and solid tumors now offered at UC San Diego Health.
The American Academy of Dermatology (AAD), in conjunction with the Firefighter Cancer Support Network, will host a free Skin Cancer Check event for an estimated 425 New York City firefighters on Saturday, June 1 at the New York City Firefighter Training Facility on Randall’s Island. The inaugural event kicks off the Academy’s Firefighter Skin Cancer Checks Initiative, a nationwide effort designed to provide free skin cancer checks to 10,000 firefighters by 2026.
ASCO, the largest event in cancer research, is approaching on May 31st. This year’s meeting promises to be particularly groundbreaking, with new findings and innovations that could revolutionize cancer treatment.
An experimental treatment made from a plant virus is effective at protecting against a broad range of metastatic cancers in mice, shows a new study from the University of California San Diego.
A recent American Academy of Dermatology survey of more than 1,000 U.S. adults revealed that outdoor workers — like those who work in construction, landscaping, emergency medical services, and postal delivery — are far more likely to get sunburned and tanned, putting themselves at increased risk for skin cancer, compared to the average American.
While skin cancer is one of the most preventable types of cancer, a recent survey of more than 1,000 U.S. adults found that an increasing number of Americans are reporting sunburn despite knowing how to protect themselves from the sun’s harmful rays.
Even though melanoma is rarer in this population, Black patients are more at risk for getting diagnosed late and having worse survival outcomes. Not all skin cancers are caused by sun exposure, and not all melanomas originate in sun-exposed areas;…
Age-related changes that cause the skin to stiffen and become less elastic may also contribute to higher rates of metastatic skin cancer in older people, according to research by investigators from the Johns Hopkins Kimmel Cancer Center.
U.S. veterans are at a higher risk of developing melanoma, one of the deadliest forms of skin cancer, likely due in part to the occupational hazards associated with active duty in countries near the equator where ultraviolet (UV) levels are higher.
Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, is one of the first centers nationwide to offer a newly approved cell-based immunotherapy that targets melanoma.
A first-of-its-kind cellular immunotherapy pioneered at Moffitt Cancer Center has received approval from the Food and Drug Administration and is now available for patients with advanced melanoma. Lifileucel is the first tumor-infiltrating lymphocyte therapy, or TIL, approved for solid tumors.
Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.
Sunscreen is important, says Dr. Ivan Litvinov, but it is also the least effective way to protect your skin when compared to sun protective clothing and sun avoidance
This special edition features upcoming oral presentations by MD Anderson researchers at the 2023 European Society for Medical Oncology (ESMO) Congress focused on clinical advances across a variety of cancer types.
Researchers at the UCLA Jonsson Comprehensive Cancer Center have identified a new role for a protein called extracellular signal-regulated kinase (ERK) in a pathway activated by interferon-gamma that can trigger cells to self-destruct.
Jennifer Wargo, M.D., professor of Surgical Oncology and Genomic Medicine at The University of Texas MD Anderson Cancer Center, has been elected to the National Academy of Medicine (NAM) for her contributions to the understanding of melanoma treatment response and resistance to cancer therapies, including groundbreaking discoveries that reveal how the gut microbiome influences responses to immunotherapy.
Circulating tumor DNA (ctDNA) is emerging as a blood-based biomarker for many solid tumor types, including melanoma.
The deletion of MTAP is primarily responsible for the decline in T cell function and lack of response to immune checkpoint inhibitors in patients whose tumor cells lack working copies of this gene.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
Although rare, mucosal melanoma in humans has a low survival rate. It has been difficult to investigate due to a lack of similar cancers in animals for study.
O mito de que pessoas com pele escura são imunes ao melanoma (um tipo de câncer de pele) persiste há muitos anos.
Hace muchos años que persiste el mito de que las personas de piel oscura son inmunes al melanoma, un tipo de cáncer de piel.
Melanoma, the most serious form of skin cancer, is highly treatable when detected early, but when the disease advances, it can lead to death. A new article published in the Journal of the American Academy of Dermatology reveals that men with melanoma — and particularly men with skin of color — are more likely to die than women with melanoma.
Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified potential new biomarkers that could indicate how someone diagnosed with metastatic melanoma will respond to immunotherapy treatment.
A new study conducted at Tel Aviv University and the Sheba Medical Center reveals how melanoma cancer cells affect their close environment to support their needs – by forming new lymph vessels in the dermis in order to go deeper into the skin and spread through the body.
In addition to presenting Sylvester Comprehensive Cancer Center research findings, Sylvester experts are available at ASCO to share perspectives on a wide variety of topics and studies ranging from breast cancer to sarcoma, prostate cancer, mesothelioma, melanoma, CNS tumors and more.
Independientemente de donde viva, la exposición al sol aumenta el riesgo de cáncer de piel. Esto es particularmente cierto en los hombres.
A recent American Academy of Dermatology survey of more than 1,000 U.S. adults revealed that many Generation Z adults, ages 18-25, are unaware of the risks associated with overexposure to the sun and believe tanning myths. In recognition of Skin Cancer Awareness Month this May, the AAD encourages everyone to practice safe sun to protect themselves from the sun’s harmful rays and reduce their risks of developing skin cancer.
One of the biggest goals of immunotherapy is to reverse T cell exhaustion to boost the immune system’s ability to destroy cancerous cells. Researchers at Sanford Burnham Prebys studying melanoma have found a new way to make this happen.
Cedars-Sinai Cancer oncologists and researchers are available to comment on late-breaking topics and research throughout the American Association for Cancer Research (AACR) Annual Meeting 2023, happening April 14-19 in Orlando.
A novel approach to administer intrathecal (IT) immunotherapy (directly into the spinal fluid) and intravenous (IV) immunotherapy was safe and improved survival in a subset of patients with leptomeningeal disease (LMD) from metastatic melanoma, according to interim analyses of a Phase I/Ib trial led by researchers at The University of Texas MD Anderson Cancer Center.
Needles are an uncomfortable but necessary aspect of vaccination. But today, scientists report steps toward an alternative, relatively painless method that can deliver biological materials to cells by “shooting” them in with air. They will present their results at ACS Spring 2023.
A team of researchers from institutions across the United States, including Moffitt Cancer Center, launched a phase 2 clinical trial evaluating a new treatment option for this patient population. Their results, published in The New England Journal of Medicine, show that treating resectable stage 3 and 4 melanoma patients with the immunotherapy drug pembrolizumab both before and after surgery greatly improves outcomes when compared to pembrolizumab given only after surgery.
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments include a new understanding of how HPV drives cancer development, a combination therapy to overcome treatment resistance in mantle cell lymphoma, novel insights into memory T cell formation and potential therapeutic strategies for brain cancers, improved survival outcomes for metastatic colorectal cancer, targeting myeloperoxidase to improve immunotherapy responses in melanoma, and preclinical results of a combination therapy that could effectively treat a subset of acute myeloid leukemia.
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu